<p>Mumbai, India; April 30, 2019: &ndash;  Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla&rdquo;) announce receipt of final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan Tablets 5mg &amp; 10mg from the United States Food and Drug Administration (US FDA).  </p>rnrn rn<p>Cipla&rsquo;s Ambrisentan Tablets 5mg &amp; 10mg is AB-rated generic therapeutic equivalent version of Gilead Sciences, Inc&rsquo;s Letairis&reg;. Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening.  </p>rnrn rn<p>The U.S. Sales of Letairis&reg; Tablets USP stood at $943 million in 2018. The product is available for shipping immediately. </p>